Effects of ciprofol on perioperative immune function and inflammatory response in patients undergoing renal transplantation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060996

Enrollment

Unknown

Registered

2022-06-15

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease

Interventions

two:Ciprofol replaces propofol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Gender unlimited; Age 18 ~ 65 years old; BMI 18 ~ 30kg / m2, ASA grade: III-IV; (2) Allogeneic kidney transplantation was performed for the first time; (3) Regular dialysis treatment before operation; (4) The family members of the patients voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Accompanied by various active infections and abnormal functions of important organs (heart, liver, lung, etc.); (2) With autoimmune diseases (SLE, etc.); (3) Coagulation dysfunction; (4) Secondary renal transplantation; (5) Unable to cooperate with the researcher due to mental disorder or mental illness.

Design outcomes

Primary

Measure	Time frame
T cell lymphoid group;	—

Countries

China

Contacts

Public ContactWeiyong Qin

Department of Anesthesiology, the Second Affiliated Hospital of Guangxi Medical University

936820238@qq.com18776847214

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026